Literature DB >> 359368

Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle.

R G Bell.   

Abstract

Vitamin K is primarily located in hepatic microsomes, where the vitamin K-dependent carboxylation in prothrombin synthesis occurs. Recent evidence supports the idea that the carboxylation is linked to the metabolism of the vitamin--specifically the cyclic interconversion of vitamin K and vitamin K epoxide. The primary site of action of coumarin and indandione anticoagulants appears to be an inhibition of the epoxide-to-vitamin K conversion in this cycle. There is a correlation between the inhibition of prothrombin synthesis and the regeneration of vitamin K from the epoxide by anticoagulants. In hamsters and warfarin-resistant rats prothrombin synthesis and the epoxide-K conversion are less sensitive to warfarin than in the normal rat. The epoxide-K conversion is impaired in resistant rats, which may explain their high vitamin K requirement. There is also a correlation between vitamin K epoxidation and vitamin K-dependent carboxylation, but the apparent link may be because vitamin K hydroquinone is an intermediate in the formation of the epoxide and also the active form in carboxylation. The vitamin K-epoxide cycle is found in extrahepatic tissues such as kidney, spleen, and lung and is inhibited by warfarin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 359368

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  19 in total

1.  Vitamin K2 promotes 1alpha,25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts.

Authors:  Y Koshihara; K Hoshi; H Ishibashi; M Shiraki
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

Review 2.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

3.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Authors:  I A Choonara; R G Malia; B P Haynes; C R Hay; S Cholerton; A M Breckenridge; F E Preston; B K Park
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

4.  Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins.

Authors:  B K Park; I A Choonara; B P Haynes; A M Breckenridge; R G Malia; F E Preston
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

5.  Plasma disposition of vitamin K1 in relation to anticoagulant poisoning.

Authors:  B K Park; A K Scott; A C Wilson; B P Haynes; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

6.  Difenacoum (Neosorexa) poisoning.

Authors:  A M Barlow; A L Gay; B K Park
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-21

Review 7.  Post-translational carboxylation of preprothrombin.

Authors:  B C Johnson
Journal:  Mol Cell Biochem       Date:  1981-08-11       Impact factor: 3.396

8.  A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit.

Authors:  A M Breckenridge; S Cholerton; J A Hart; B K Park; A K Scott
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

9.  Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man.

Authors:  H Bechtold; D Trenk; T Meinertz; M Rowland; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  The influence of age, liver size and enantiomer concentrations on warfarin requirements.

Authors:  H Wynne; L Cope; P Kelly; T Whittingham; C Edwards; F Kamali
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.